The FDA granted orphan drug designation to rexlemestrocel-L for the prevention of postimplantation mucosal bleeding in patients with end-stage chronic heart failure who require a left ventricular assist device.
Rexlemestrocel-L (Revascor; Mesoblast) is an investigational allogeneic mesenchymal precursor cell therapy under development for injection into the heart muscle in patients with moderate to advanced or end-stage chronic HF.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.